Home / Membership-Basic  / Theralase Technologies Inc. Upends Cancer Research with Immune System Response

Theralase Technologies Inc. Upends Cancer Research with Immune System Response

by James West

Therelase Technologies Inc. (TSX.V:TLT) has set the cancer research world abuzz with the discovery that its photodynamic compound treatment for bladder cancer has resulted in a defacto immunization against future recurrence of the deadly disease in mice. Photodynamic compounds are chemicals which, when injected into a tumour and exposed to specific bandwidths of light destroy cancerous cells while leaving healthy tissue unharmed. Watch the Interview with Roger White, CEO of Theralase at the Canadian Investment Conference: While there are instances…...

This is a Premium Article.

NO COMMENTS

Sorry, the comment form is closed at this time.

Sign up for our free newsletter

& get more of MidasLetter delivered to your inbox.